Swiss Rockets, a Basel-based incubator and accelerator for start-up companies specializing in oncology and infectiology, has partnered with Serbia to advance oncology and nuclear medicine.
At the end of July, the Serbian Minister of Science, Technological Development, and Innovation, Jelena Begovic, and the CEO of Swiss Rockets AG, Dr. Vladimir Cmiljanovic, signed a Memorandum of Understanding in the Serbian capital Belgrade. This cooperation heralds new opportunities for the development of oncology and nuclear medicine.
After the signing, Minister Begovic highlighted the contributions of Serbian nationals in Switzerland who laid the foundation for Swiss Rockets AG, a pioneering company with numerous innovations. She said, "It is encouraging to see that these innovators have decided to bring their expertise and cutting-edge technologies to Serbia.”
Swiss Rockets AG has committed to establishing a state-of-the-art nuclear medicine innovation center within the BIO4 campus (www.bio4.rs). Expanding on the cooperation, Minister Begovic said, "The company will strengthen the ecosystem of biotechnology start-ups in Serbia. In addition, they have already started collaborations with our leading scientific and research institutes, such as INEP and the Institute of Chemistry, Technology and Metallurgy (IHTM)".
Dr. Cmiljanovic explained their vision: "Our goal is to establish a theranostic innovation center in Serbia within the innovative biotechnology campus BIO4. This facility will reflect the caliber of top hospitals and enable the production of the latest molecules tailored for cancer treatment. Using the latest scanning technologies, we can identify patients with metastases. Using this data, we can then provide personalized treatment protocols.”
Underscoring the importance of this partnership, Dr. Cmiljanovic added, "Our alliance with Serbia is more than just a technology transfer; it's a commitment to develop and advance these technologies together here. This initiative is of paramount importance to those battling cancer, particularly diseases such as metastatic prostate cancer, neuroendocrine tumors, glioblastoma, and breast cancer."